Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

List/tripsitting: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Graham
adding distinction of variant and invariant treatments and explanation about why there aren't antidotes listed for stimulants.
>Graham
m Note regarding advisory counsel
Line 181: Line 181:
                 <li class="featured list-item">
                 <li class="featured list-item">
<h4 class="media-heading">[[Dealing with stimulant psychosis]]</h4>
<h4 class="media-heading">[[Dealing with stimulant psychosis]]</h4>
* Cautionary note: the combination of being on dopaminergic agonists and attempting to stop their effects with dopaminergic antagonists may result in a life-threatening condition known as [https://en.wikipedia.org/wiki/Neuroleptic_malignant_syndrome neuroleptic malignant syndrome.]
*Cautionary note: the combination of being on dopaminergic agonists and attempting to stop their effects with dopaminergic antagonists may result in a life-threatening condition known as [https://en.wikipedia.org/wiki/Neuroleptic_malignant_syndrome neuroleptic malignant syndrome.]
                 </li>
                 </li>
             </ul>
             </ul>
Line 193: Line 193:
                 <li class="featured list-item">
                 <li class="featured list-item">
<h4 class="media-heading">[[PTSD treatments|PTSD treatment]]</h4>
<h4 class="media-heading">[[PTSD treatments|PTSD treatment]]</h4>
*[[MDMA-AP]]
*[[MDMA-AP|MDMA Therapy]]
**Note: proposed paradigms have been advised against implementation due to  methodological problems.
                 </li>
                 </li>
                 <li class="featured list-item">
                 <li class="featured list-item">

Revision as of 20:29, 26 June 2024



Cannabinoid tripsitting

Miscellaneous hallucinogen tripsitting

Depressant tripsitting

Stimulant tripsitting

Entactogen tripsitting

  1. Czégény, Z; Nagy, G; Babinszki, B; Bajtel, Á; Sebestyén, Z; Kiss, T; Csupor-Löffler, B; Tóth, B; Csupor, D (26 April 2021). "CBD, a precursor of THC in e-cigarettes". Scientific reports. 11 (1): 8951. doi:10.1038/s41598-021-88389-z. PMID 33903673. 
  2. Englund, A., Oliver, D., Chesney, E., Chester, L., Wilson, J., Sovi, S., De Micheli, A., Hodsoll, J., Fusar-Poli, P., Strang, J., Murray, R. M., Freeman, T. P., McGuire, P. (16 November 2022). "Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios". Neuropsychopharmacology: 1–8. doi:10.1038/s41386-022-01478-z. ISSN 1740-634X. Retrieved 25 November 2022.